IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Diabetic Retinopathy: A Review On It's Pathophysiology And Novel Treatment Modalities

[1]Sakshi Dadge, [2]Ashvini D. Nagare, [3]Dr. Vijaykumar Kale, [4]Dr. Mahesh Thakare, [5]Asst. Prof. Vaibhav Narwade

[1]Student, [2]Assistant Professor, [3]Principal, [4]Associate Professor, [5]Assistant Professor
[1]Department of B. Pharm,
[1]Kasturi Shikshan Sanstha college of Pharmacy, Shikrapur, India.

***Abstract**:* Diabetic retinopathy (DR) represents a major microvascular complication of diabetes mellitus and remains the leading cause of preventable blindness in working-aged adults worldwide. With the global burden of diabetes escalating, the prevalence of DR is projected to increase from 103.12 million affected individuals in 2020 to 160.5 million by 2045. The pathophysiology of DR involves complex, interconnected biochemical pathways including polyol pathway activation, advanced glycation end-product formation, protein kinase C dysregulation, and oxidative stress, all of which culminate in retinal vascular dysfunction, inflammation, and neurodegeneration. Traditionally managed through laser photocoagulation and vitrectomy, DR treatment has been revolutionized by anti-vascular endothelial growth factor therapies. Recent advances have introduced novel therapeutic modalities including next-generation bispecific antibodies such as faricimab, gene therapy approaches targeting mechanistic pathways, stem cell-based regenerative treatments, and systemic agents like sodium-glucose cotransporter-2 inhibitors. This comprehensive review examines the molecular mechanisms underlying DR pathogenesis, discusses established treatment paradigms, and explores emerging therapeutic strategies that promise to transform disease management and improve visual outcomes for millions of patients globally.

***Index Terms* -** Diabetic retinopathy, pathophysiology, anti-VEGF therapy, gene therapy, novel treatments, stem cell therapy.

I. INTRODUCTION

Diabetic retinopathy (DR) is a sight-threatening microvascular complication that develops in individuals with prolonged hyperglycemia, affecting approximately one-third of all diabetic patients globally[1,3]. As a leading cause of vision impairment among working-age adults, DR poses significant public health and socioeconomic challenges worldwide[1,3]. The International Diabetes Federation estimated that 529 million people were living with diabetes in 2021, and this number continues to rise exponentially[2]. Consequently, the global prevalence of DR among diabetic individuals is estimated at 22.27%, translating to over 103 million affected adults in 2020, with projections suggesting this figure will reach 160.5 million by 2045[2].

The distribution of DR varies considerably across geographical regions, with the highest prevalence observed in Africa at 35.9% and North America at 33.3%, while South and Central America report the lowest prevalence at 13.4%[2]. Vision-threatening diabetic retinopathy, which includes proliferative diabetic retinopathy and diabetic macular edema, affects approximately 6.17% of diabetic patients, representing 28.54 million individuals worldwide[2]. These alarming statistics underscore the urgent need for enhanced understanding of disease mechanisms and development of more effective therapeutic interventions. The natural history of DR progresses from mild non-proliferative changes characterized by microaneurysms to severe proliferative disease with neovascularization, potentially culminating in tractional retinal detachment and irreversible vision loss[5,11].

Traditional management strategies have primarily focused on laser photocoagulation and surgical intervention through vitrectomy, which, while effective in preventing progression, often result in significant collateral retinal damage[5,11]. The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy revolutionized DR management, offering improved visual outcomes with reduced invasiveness[6,12]. However, the requirement for frequent intravitreal injections and variable patient response have necessitated the continued search for more durable and comprehensive treatment options[7,12]. This review provides a detailed examination of DR pathophysiology, encompassing the molecular mechanisms that drive disease progression, and surveys both established and emerging therapeutic modalities that hold promise for improving patient outcomes in this devastating condition[7,10].

II. PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY



Fig 1: Pathophysiology flowchart.

2.1 Molecular Mechanisms and Biochemical Pathways

The pathogenesis of diabetic retinopathy is multifactorial, involving an intricate network of metabolic perturbations initiated by chronic hyperglycemia that ultimately leads to retinal microvascular damage and neurodegeneration[3,8]. At the molecular level, persistent elevation of blood glucose triggers activation of several aberrant metabolic pathways that converge to produce oxidative stress, inflammation, and vascular dysfunction[3,8]. The polyol pathway represents one of the earliest metabolic derangements, wherein excess glucose is converted to sorbitol by the enzyme aldose reductase, with sorbitol subsequently oxidized to fructose by sorbitol dehydrogenase[9,12]. Sorbitol accumulation within retinal cells causes osmotic stress due to its impermeability across cellular membranes, while the increased flux through this pathway depletes nicotinamide adenine dinucleotide phosphate (NADPH), thereby compromising antioxidant defense mechanisms and rendering cells vulnerable to oxidative damage[9,12].

Advanced glycation end-products (AGEs) constitute another critical pathogenic mechanism in DR development. These irreversible protein modifications result from non-enzymatic glycation of proteins, lipids, and nucleic acids under hyperglycemic conditions[10,13]. AGEs exert their deleterious effects through direct structural alterations of extracellular matrix proteins and through inter action with receptors for AGEs (RAGE) on endothelial cells, pericytes, and inflammatory cells, thereby activating nuclear factor-kappa B (NF-κB) and initiating a cascade of inflammatory responses[10,13]. The AGE-RAGE axis promotes oxidative stress generation, increases vascular permeability, stimulates expression of pro-inflammatory cytokines, and accelerates apoptosis of retinal capillary cells[10,13]. Concurrently, protein kinase C (PKC) activation occurs as a consequence of hyperglycemia-induced diacylglycerol synthesis, with the PKC-β isoform particularly implicated in DR pathogenesis[11,12]. PKC activation leads to overexpression of vascular endothelial growth factor (VEGF), increased retinal blood flow, vascular permeability, and leukocyte adhesion, all of which contribute to blood–retinal barrier breakdown[11,12].

2.2 Oxidative Stress and Inflammation

Oxidative stress serves as a central mediator in DR pathogenesis, arising from hyperglycemia-induced mitochondrial dysfunction and excessive production of reactive oxygen species (ROS)[12,14]. Mitochondrial overproduction of superoxide radicals inhibits glyceraldehyde-3-phosphate dehydrogenase activity, leading to accumulation of glycolytic intermediates that fuel the polyol pathway, AGE formation, and PKC activation, thereby creating a self-perpetuating cycle of oxidative damage[12,14]. Furthermore, ROS activate poly(ADP-ribose) polymerase (PARP), which consumes NAD^+ and inhibits glycolytic enzymes, exacerbating cellular energy depletion and promoting endothelial cell dysfunction[12,14]. The retina, with its high metabolic activity and abundant polyunsaturated fatty acids, is particularly susceptible to oxidative injury, manifesting as lipid peroxidation, DNA damage, and mitochondrial dysfunction that culminate in apoptosis of retinal neurons and vascular cells[12,14].

Chronic low-grade inflammation represents an equally important component of DR pathogenesis, characterized by elevated levels of pro-inflammatory cytokines including interleukin-1β, interleukin-6, and tumor necrosis factor-alpha in the diabetic retina[11,15]. Leukocyte adhesion to retinal vascular endothelium, mediated by upregulation of intercellular adhesion molecule-1 (ICAM-1) and CD18, leads to capillary occlusion and localized ischemia[11,15]. These inflammatory processes compromise the integrity of the blood–retinal barrier through disruption of tight junction proteins such as occludin and zonula occludens-1, resulting in increased vascular permeability and accumulation of extravascular fluid characteristic of diabetic macular edema[2,6]. The inflammatory milieu further amplifies VEGF expression, establishing a pathological environment conducive to neovascularization in advanced disease stages[11,15].

2.3 Vascular Abnormalities and Neurodegeneration

The hallmark vascular changes in DR commence with microaneurysm formation, representing focal outpouchings of retinal capillaries due to pericyte loss and weakening of the capillary wall[5,11]. Progressive pericyte apoptosis, accelerated by oxidative stress and AGE accumulation, leads to loss of capillary structural support and regulatory function[11,13]. As DR advances, capillary basement membrane thickening, endothelial cell proliferation, and eventual capillary occlusion result in progressive retinal ischemia[5,11]. The ischemic retina responds by upregulating VEGF expression, which serves as a potent stimulus for pathological neovascularization[2,6]. These newly formed blood vessels exhibit abnormal architecture, lacking the structural integrity of normal retinal vasculature, and are prone to hemorrhage into the vitreous cavity and proliferation with fibrovascular membrane formation[5,11]. Contraction of these fibrovascular membranes can exert tractional forces on the retina, potentially causing tractional retinal detachment and severe vision loss[5,11].

Emerging evidence highlights the significant role of neurodegeneration in DR pathophysiology, challenging the traditional view of DR as purely a vascular disease[8,15]. Retinal ganglion cells, the earliest neurons affected in DR, undergo accelerated apoptosis due to oxidative stress, glutamate excitotoxicity, and depletion of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and pigment epithelium-derived factor (PEDF)[8,15]. Electroretinographic studies demonstrate functional abnormalities in the diabetic retina that precede clinically detectable vascular changes, suggesting that neuronal dysfunction represents an early and potentially reversible component of DR[8]. Inner retinal thinning, detected by optical coherence tomography even in patients with minimal or no visible retinopathy, further corroborates the neurodegenerative aspect of DR pathogenesis[8,15]. Recognition of this neurovascu lar paradigm has important therapeutic implications, suggesting that neuroprotective strategies may complement traditional anti- angiogenic approaches in comprehensive DR management[8,18].

III. CLASSIFICATION AND RISK FACTORS



Fig 2: Diabetic Retoripathy: Clinical Staging and Progression.

3.1 Clinical Staging of Diabetic Retinopathy

Diabetic retinopathy is clinically categorized into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), with NPDR further subdivided into mild, moderate, and severe stages based on the extent and severity of retinal findings[5,11]. Mild NPDR, the earliest clinically detectable stage, is characterized by the presence of microaneurysms, which appear as small red dots on fundoscopic examination and represent focal dilations of retinal capillaries[5]. Although visual acuity typically remains unaffected at this stage, the presence of microaneurysms signals that microvascular damage has commenced and that the patient faces increased risk of disease progression[5,11]. Moderate NPDR demonstrates more extensive vascular abnormalities, including retinal hemorrhages, cotton-wool spots representing focal nerve fiber layer infarctions, hard exudates from lipid deposition, and venous caliber changes[5,11]. At this stage, some blood vessels become blocked, restricting blood supply to specific retinal areas and potentially affecting the macula, thereby causing vision impairment if macular edema develops[2,6].

Severe NPDR, also known as preproliferative diabetic retinopathy, is defined by the "4-2-1 rule": severe retinal hemorrhages in all four quadrants, venous beading in two or more quadrants, or intraretinal microvascular abnormalities (IRMA) in one or more quadrants[5,11]. These findings indicate significant retinal ischemia and herald a high likelihood of progression to proliferative disease if left untreated[5]. Proliferative diabetic retinopathy represents the most advanced and vision-threatening stage, characterized by pathological neovascularization either on the optic disc or elsewhere on the retina[5]. These fragile new vessels readily hemorrhage into the vitreous cavity, causing sudden vision loss, and proliferate with fibrovascular tissue that can contract and produce tractional retinal detachment[5,11]. Diabetic macular edema (DME), defined as retinal thickening involving or threatening the fovea, can occur at any stage of DR and represents the most common cause of vision loss in diabetic patients[2,6].

3.2 Risk Factors for Disease Development and Progression

Multiple systemic and ocular risk factors influence the development and progression of diabetic retinopathy, with hyperglycemia identified as the dominant modifiable risk factor[13,14]. The landmark Diabetes Control and Complications Trial (DCCT) for type 1 diabetes and the United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes definitively established that intensive glycemic control significantly reduces the incidence and slows the progression of DR[14]. Each one percent increase in glycated hemoglobin (HbA1c) is associated with a corresponding increase in DR risk, and maintaining HbA1c levels below 7% substantially reduces the likelihood of developing vision-threatening complications[13,14]. The duration of diabetes emerges as another critical non- modifiable risk factor, with DR prevalence increasing from approximately 20% at 5 years to nearly 60% after 10 years of diabetes duration in patients with type 2 diabetes[3].

Systemic hypertension constitutes an important independent risk factor for DR development and progression, with studies demonstrating that diabetic patients with concurrent hypertension have a 1.7-fold increased relative risk of developing retinopathy[14]. The pathophysiological basis for this association involves multiple mechanisms, including endothelial dysfunction, increased oxidative stress, and dysregulation of the renin–angiotensin–aldosterone system that synergistically promote retinal vascular damage[14]. Effective blood pressure control, targeting values below 140/90 mmHg, has been shown to reduce the rate of DR worsening by 34% over long-term follow-up[14]. Dyslipidemia, particularly elevated total cholesterol, low-density lipoprotein cholesterol, and triglycerides, correlates with increased risk of hard exudates and vision loss in diabetic patients[14]. Central obesity, measured by waist–hip ratio, represents an independent risk factor, likely mediated through insulin resistance, chronic inflammation, and metabolic syndrome[13,19]. Additional risk factors include pregnancy, puberty, cataract surgery, and genetic predisposition, all of which may accelerate DR progression through various pathophysiological mechanisms[3,14].

IV. ESTABLISHED TREATMENT MODALITIES

4.1 Laser Photocoagulation

Laser photocoagulation has served as a cornerstone of DR management for nearly five decades, with panretinal photocoagulation (PRP) remaining the gold standard treatment for proliferative diabetic retinopathy[5,11,15]. The therapeutic principle underlying PRP involves applying multiple laser burns to the peripheral retina, thereby ablating ischemic tissue and reducing oxygen demand, which in turn decreases production of angiogenic factors such as VEGF and halts pathological neovascularization[11,15]. The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated that timely PRP reduces the risk of severe vision loss by 50% in eyes with high-risk proliferative disease[15]. Traditional argon laser systems require prolonged treatment sessions and cause considerable patient discomfort due to extensive thermal tissue destruction extending beyond the targeted retinal pigment epithelium (RPE) to affect the neurosensory retina[5,15].

Technological advances have yielded several improved laser platforms that minimize collateral damage while maintaining therapeutic efficacy. Pattern-scanning laser systems, such as the PASCAL (Pattern Scan Laser), enable rapid delivery of multiple laser spots in predetermined geometric patterns with shorter pulse durations of 10–20 milliseconds compared to conventional systems using 100–200 milliseconds[6,13]. This abbreviated exposure time reduces lateral thermal spread to adjacent tissue, diminishes pain perception, and shortens treatment duration, thereby enhancing patient compliance and reducing procedural complications[6,13]. Subthreshold diode micropulse laser represents another innovative approach, delivering laser energy in microsecond pulses separated by rest periods, which allows thermal dissipation and prevents visible retinal burns while selectively targeting the RPE[6,13]. This technique has shown promise in treating diabetic macular edema without causing the permanent scotomas associated with conventional focal laser therapy[6]. Navigational laser systems utilizing fundus imaging and eye-tracking technology facilitate precise, predetermined laser placement with enhanced accuracy, potentially improving outcomes in DME management[6,13].

4.2 Vitreoretinal Surgery

Pars plana vitrectomy has become an essential surgical intervention for advanced complications of proliferative diabetic retinopathy that cannot be managed with laser or pharmacological therapy alone[11,15]. The primary indications for diabetic vitrectomy include non-clearing vitreous hemorrhage persisting beyond 4 weeks despite conservative management, tractional retinal detachment threatening or involving the macula, combined tractional–rhegmatogenous retinal detachment, and refractory diabetic macular edema with vitreomacular traction[15,18]. Non-clearing vitreous hemorrhage represents the most common indication, as persistent blood opacification prevents adequate retinal visualization for laser treatment and monitoring of disease progression[15]. Surgical intervention aims to clear the vitreous cavity, remove fibrovascular proliferation, relieve tractional forces on the retina, and enable complete panretinal photocoagulation when necessary[15].

Modern vitrectomy employs small-gauge instrumentation (23-gauge, 25-gauge, or 27-gauge) that permits sutureless transconjunctival surgery with faster recovery and reduced postoperative inflammation compared to traditional 20-gauge techniques[15]. Surgical maneuvers in complex diabetic cases require meticulous dissection of fibrovascular membranes using bimanual techniques, judicious application of endodiathermy to achieve hemostasis, segmentation and delamination techniques to relieve tractional forces, and intraoperative endolaser photocoagulation[15]. Adjunctive use of vital dyes such as triamcinolone acetonide for vitreous visualization and brilliant blue for internal limiting membrane identification facilitates safer membrane peeling[15]. Pre-operative intravitreal anti-VEGF injection administered 3–7 days before surgery has been shown to reduce intraoperative bleeding, improve surgical field visibility, and potentially enhance postoperative visual outcomes[15,18]. Long-acting gas tamponade or silicone oil may be necessary in cases with combined retinal detachment to maintain retinal attachment during the healing process[15].

4.3 Anti-VEGF Therapy: Established Agents

The introduction of anti-vascular endothelial growth factor therapy revolutionized the management of diabetic macular edema and has demonstrated efficacy in preventing progression of non-proliferative diabetic retinopathy to proliferative stages[6,12]. Ranibizumab, a 48-kilodalton humanized monoclonal antibody fragment specifically designed for intraocular use, binds to all active isoforms of VEGF-A with high affinity, thereby neutralizing its biological activity and reducing vascular permeability and neovascularization[6,12]. The RISE and RIDE clinical trials established ranibizumab's efficacy in DME treatment, demonstrating mean visual acuity improvements of 10–12 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and 75–80% reduction in risk of progression to proliferative disease with monthly administration[6,12]. Aflibercept represents a recombinant fusion protein combining portions of VEGF receptor-1 and receptor-2 with the Fc portion of human immunoglobulin G1, creating a 115-kilodalton molecule that functions as a VEGF-trap by binding VEGF-A, VEGF-B, and placental growth factor with higher affinity than native receptors[6,12].

Comparative effectiveness studies have demonstrated that aflibercept and ranibizumab produce similar functional and anatomical outcomes in DME management, with no statistically significant differences in best-corrected visual acuity gains or central subfield thickness reduction over 6–12 months of treatment[7]. Both agents require initial monthly loading doses followed by maintenance therapy at 4–8 week intervals, necessitating frequent clinic visits and intravitreal injections that impose significant treatment burden on patients and healthcare systems[6,7]. Long-term studies indicate that sustained improvement requires continued therapy over multiple years, with discontinuation often resulting in recurrence of macular edema and vision decline[7]. The safety profiles of these agents are generally favorable, with endophthalmitis occurring in less than 0.1% of injections, although concerns exist regarding potential systemic cardiovascular effects, particularly in elderly patients with pre-existing vascular disease[6,12]. Despite these limitations, anti-VEGF therapy has become the first-line treatment for center-involving diabetic macular edema and has reduced the need for panretinal laser photocoagulation in many patients with proliferative disease[6,7].

4.4 Corticosteroid Therapy

Intravitreal corticosteroids represent an important alternative therapeutic option for diabetic macular edema, particularly in patients who respond inadequately to anti-VEGF therapy or who have contraindications to anti-VEGF agents[16]. The pathophysiological rationale for corticosteroid use in DME stems from their pleiotropic anti-inflammatory effects, including suppression of inflammatory cytokines, inhibition of leukocyte adhesion, stabilization of the blood–retinal barrier through upregulation of tight junction proteins, and reduction of VEGF expression[16]. Dexamethasone intravitreal implant (Ozurdex), a biodegradable sustained- release device containing 0.7 milligrams of dexamethasone, provides therapeutic drug levels for up to 6 months following a single injection[16]. The pivotal MEAD clinical trials demonstrated significant visual acuity improvements and central retinal thickness reduction with dexamethasone implant, with peak therapeutic effect observed 2–3 months post-injection[16].

Current clinical practice guidelines recommend corticosteroids primarily as second-line therapy for DME cases demonstrating suboptimal response to anti-VEGF treatment, defined as less than 50% reduction in excess macular thickness after 3–4 monthly anti-VEGF injections[16]. Dexamethasone implant has shown particular efficacy in pseudophakic eyes, where it may be considered as first-line therapy given the absence of cataract progression risk in these patients[16]. Post-injection monitoring should emphasize assessment of intraocular pressure, as approximately 30% of patients experience IOP elevation requiring topical medication, with 1–2% necessitating surgical intervention for pressure control[16]. Cataract progression occurs in nearly all phakic patients receiving multiple implants over time, although this can be addressed with cataract surgery when visually significant[16]. Retrospective analyses of MEAD trial data revealed that dexamethasone implant not only improves macular edema but also demonstrates potential for reducing diabetic retinopathy severity, with approximately 30% of treated eyes showing improvement of two or more steps on the Diabetic Retinopathy Severity Scale[16].

V. NOVEL AND EMERGING TREATMENT MODALITIES



Fig 3: Treatment modalities comparison.

5.1 Next-Generation Anti-VEGF Agents

The limitations of current anti-VEGF therapies, particularly the need for frequent intravitreal injections and variable treatment response, have spurred development of novel bispecific antibodies and longer-acting agents designed to extend dosing intervals while maintaining or improving efficacy[7,17]. Faricimab represents the first bispecific antibody approved for diabetic macular edema, simultaneously targeting both VEGF-A and angiopoietin-2 (Ang-2) through independent binding sites[17]. This dual mechanism addresses two complementary pathways critical to DR pathogenesis: VEGF-driven vascular permeability and neovascularization, and Ang-2-mediated vascular destabilization and inflammation[17]. The phase 3 YOSEMITE and RHINE trials enrolled over 1,800 treatment-naïve DME patients randomized to receive faricimab with personalized treat-and-extend dosing, faricimab every 8 weeks, or aflibercept every 8 weeks[17]. Results demonstrated that faricimab achieved robust vision gains of 10.7–11.8 ETDRS letters at one year, non-inferior to aflibercept, with the personalized dosing arm achieving treatment intervals extending up to 16 weeks in 60% of patients[17].

The anatomical improvements observed with faricimab, including significant reductions in central subfield thickness and resolution of intraretinal and subretinal fluid, were accompanied by improvements in diabetic retinopathy severity, with approximately 46% of patients in the YOSEMITE trial demonstrating two or more step improvement on the Diabetic Retinopathy Severity Scale[17]. Real-world evidence from the FARWIDE-DMO study corroborates the clinical trial findings, demonstrating that treatment-naïve eyes gained approximately 5 letters of vision at 12 months with reduced injection frequency in the second 6 months compared to the initial treatment period[17]. Brolucizumab, a 26-kilodalton single-chain antibody fragment with higher molar concentration per injection volume than current agents, has demonstrated promising results in phase 3 trials for neovascular age-related macular degeneration and is under investigation for diabetic retinopathy[18]. Other investigational agents including KSI-301, a biopolymer conjugate designed for extended durability, are in clinical development with the goal of further extending treatment intervals and reducing injection burden[7,18].

5.2 Gene Therapy Approaches

Gene therapy represents a paradigm-shifting approach in DR management, offering the potential for sustained therapeutic effect from a single treatment by enabling long-term expression of therapeutic proteins within the eye[9,18]. The anatomical and immunological characteristics of the eye, including its small compartment size, relative immune privilege, and accessibility for direct drug delivery, make it an ideal target organ for gene therapy applications[18]. ABBV-RGX-314, a recombinant adeno-associated virus vector encoding a VEGF-neutralizing fusion protein, is being investigated as a one-time gene therapy for diabetic retinopathy and diabetic macular edema[9]. The phase 2 ALTITUDE trial evaluated suprachoroidal delivery of ABBV-RGX-314 in patients with moderately severe to severe NPDR or mild PDR, with one-year results demonstrating that 100% of patients receiving the higher

dose level achieved stable or improved disease severity[9].

Mechanistic target of rapamycin (mTOR) inhibition through gene therapy has emerged as a promising strategy addressing multiple pathogenic pathways simultaneously, given mTOR's central role in regulating cell metabolism, growth, proliferation, and angiogenesis[9,18]. Studies utilizing recombinant AAV2 vectors encoding short hairpin RNA against mTOR (rAAV2-shmTOR-SD) in diabetic mouse models demonstrated effective retinal transduction with sustained mTOR downregulation, resulting in marked reductions in pericyte loss, acellular capillary formation, vascular permeability, and retinal cell layer thinning[9]. The anti-apoptotic and anti-angiogenic effects of mTOR inhibition suggest this approach may address both the vascular and neurodegenerative components of DR pathogenesis[9,18]. Neuroprotective gene therapy strategies focus on augmenting expression of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF), which have demonstrated efficacy in preserving retinal ganglion cells and preventing neural apoptosis in preclinical models[18]. AAV-mediated delivery of anti-vasopermeability factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and vasoinhibin has shown promise in reducing blood–retinal barrier breakdown and improving retinal function in diabetic animal models[18].

5.3 Stem Cell-Based Regenerative Therapies

Stem cell therapy offers potential for retinal regeneration and neuroprotection in diabetic retinopathy through multiple mechanisms including paracrine secretion of growth factors, differentiation into retinal cell types, immunomodulation, and promotion of endogenous repair processes[19]. Mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, or umbilical cord blood have demonstrated particular promise due to their multipotent differentiation capacity, immunomodulatory properties, and relative ease of isolation and expansion[19]. In preclinical studies, intravitreal injection of neural stem cells derived from umbilical cord mesenchymal stem cells in diabetic rats resulted in long-term preservation of retinal function for up to 8 weeks post- transplantation[19]. Treated animals demonstrated significantly increased expression of BDNF and Thy-1, markers of neuronal health, along with increased survival of retinal ganglion cells and reduced progression of vascular dysfunction as measured by decreased Evans blue dye leakage[19].

Adipose-derived stem cells have shown capability to differentiate into pericyte-like cells and integrate into retinal vasculature, where they stabilize capillaries and prevent endothelial cell apoptosis and capillary dropout[19]. Studies in oxygen-induced retinopathy mouse models and diabetic Akimba mice demonstrated that intravitreally injected adipose stem cells reduced retinal endothelial apoptosis by 50% and capillary dropout by 80%, with beneficial effects enhanced by pretreatment with transforming growth factor- beta 1 to promote pericyte phenotype[19]. The therapeutic mechanisms underlying MSC benefits appear to involve both direct cellular effects and paracrine actions through secretion of anti-inflammatory cytokines, antioxidant factors, and neurotrophic proteins that create a permissive environment for endogenous repair[19]. Although most stem cell research in DR remains in preclinical stages, several phase 1 and 2 clinical trials are currently evaluating the safety and preliminary efficacy of bone marrow and adipose mesenchymal stem cells in patients with early-stage diabetic retinopathy[19]. Key challenges requiring resolution before widespread clinical application include determination of optimal cell source, delivery method, dosing regimen, and patient selection criteria, as well as establishment of long-term safety profiles[19].

5.4 Systemic Agents: SGLT2 Inhibitors and Oral Therapies

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of oral antidiabetic medications that reduce blood glucose by promoting urinary glucose excretion, have emerged as promising agents for preventing diabetic retinopathy beyond their primary metabolic effects[20]. Large retrospective cohort studies from Taiwan involving over 200,000 propensity-matched pairs of patients with type 2 diabetes demonstrated that SGLT2 inhibitor use was associated with significantly lower risk of sight-threatening retinopathy compared to other second-line oral antidiabetic agents[20]. Specifically, SGLT2 inhibitors conferred a 43% risk reduction compared to dipeptidyl peptidase-4 inhibitors, 38% reduction versus sulfonylureas, and 25% reduction compared to pioglitazone after adjusting for confounding variables including age, diabetes duration, glycemic control, and comorbidities[20]. The cumulative incidence of sight-threatening retinopathy per 1000 person-years was 3.52 for SGLT2 inhibitor users compared to 6.13 for DPP-4 inhibitor users, demonstrating substantial absolute risk reduction[20].

The retinoprotective mechanisms of SGLT2 inhibitors likely extend beyond glycemic control and may involve direct effects on retinal microvascular physiology, including reduction of oxidative stress through decreased mitochondrial glucose oxidation, inhibition of inflammatory pathways, preservation of pericytes, and modulation of retinal neuronal function[20]. Preclinical studies using streptozotocin-induced diabetic rats treated with SGLT2 inhibitors demonstrated prevention of electroretinogram abnormalities and preservation of motor nerve conduction velocity, suggesting beneficial effects on retinal neural regulatory mechanisms[20]. Other investigational oral therapies targeting specific pathogenic pathways in DR include aldose reductase inhibitors to block polyol pathway activation, angiotensin-converting enzyme inhibitors for their anti-inflammatory and antioxidant properties, and rho kinase inhibitors that may reduce vascular permeability and inflammation[9,18]. APX3330, an inhibitor of apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1), showed promise in phase 2 trials for preventing DR progression; although it did not meet the primary endpoint of two-step DRSS improvement, it demonstrated significant reduction in disease worsening[9].

VI. SCREENING AND PREVENTION STRATEGIES

Early detection through systematic screening programs remains crucial for preventing vision loss from diabetic retinopathy, given that timely intervention during asymptomatic stages can prevent progression to vision-threatening disease[21]. Current international guidelines recommend that patients with type 1 diabetes undergo annual comprehensive dilated eye examinations beginning 5 years after diabetes onset, while type 2 diabetic patients should be screened at the time of diagnosis and annually thereafter, as significant retinopathy may already be present at diabetes detection[14,21]. Pregnant women with pre-existing diabetes require examination during the first trimester with close follow-up throughout pregnancy and postpartum period due to risk of rapid progression during gestation[21]. The sensitivity of screening methods varies considerably, with direct ophthalmoscopy through dilated pupils demonstrating 65.7% sensitivity and 93.8% specificity when performed by trained observers, while non-mydriatic digital fundus photography achieves superior sensitivity of 87.3% with 84.8% specificity[21].

Recent technological advances have introduced artificial intelligence-enabled screening platforms that analyze fundus photographs to detect referable diabetic retinopathy with accuracy comparable to or exceeding human graders[22]. These AI systems can be deployed at primary care facilities and community health centers, enabling earlier detection and reducing the burden on specialist ophthalmology services[22].

India's revised national guidelines for 2025 advocate for a three-tier screening approach: AI-enabled fundus imaging at primary level for early detection, optical coherence tomography at secondary level for identifying diabetic macular edema, and advanced imaging including fluorescein angiography and OCT-angiography at tertiary centers for complex cases[22]. Primary prevention strategies emphasize optimal metabolic control, with intensive glycemic management reducing DR incidence by 76% in type 1 diabetes and 25% in type 2 diabetes according to DCCT and UKPDS trials[14]. Blood pressure control targeting less than 140/90 mmHg provides additional benefit, reducing DR progression risk by one-third[14]. Lifestyle modifications including regular physical activity, healthy diet, smoking cessation, and management of dyslipidemia complement pharmacological interventions in comprehensive risk factor modification strategies[13, 14].

VII. CONCLUSION

Diabetic retinopathy represents a complex, multifactorial microvascular complication of diabetes mellitus that continues to pose significant challenges to global eye health despite substantial advances in understanding and treatment, with its pathophysiology involving intricate interplay of metabolic perturbations, oxidative stress, inflammation, and neurovascular dysfunction that culminate in progressive retinal damage and vision impairment; traditional therapeutic approaches including laser photocoagulation and vitrectomy have provided invaluable tools for preventing blindness in advanced disease, while the advent of anti-VEGF therapy revolutionized management of diabetic macular edema and proliferative retinopathy, yet the requirement for frequent intravitreal injections and variable patient response to current therapies underscore the need for more durable and comprehensive treatmen t strategies; the emerging therapeutic landscape offers considerable promise for transforming DR management through multiple innovative modalities such as next-generation bispecific antibodies like faricimab, which demonstrate potential for extended dosing intervals while maintaining robust efficacy, gene therapy approaches targeting key pathogenic pathways that provide the possibility of sustained therapeutic effect from single treatments, and stem cell-based regenerative therapies that address both vascular and neurodegenerative components of DR pathogenesis, while systemic agents including SGLT2 inhibitors represent a paradigm shift toward systemic modification of microvascular risk; as these novel modalities progress through clinical development and enter clinical practice, they hold substantial potential for improving visual outcomes and quality of life for the millions of individuals affected by diabetic retinopathy worldwide, and continued research elucidating disease mechanisms, optimizing treatment algorithms, and enhancing screening strategies will be essential for realizing the goal of eliminating preventable blindness from this devastating complication of diabetes.

ACKNOWLEDGMENT

The authors acknowledge the contributions of researchers and clinicians whose work has significantly advanced the understanding of diabetic retinopathy, particularly in elucidating its pathophysiology and in the development of novel and emerging treatment modalities that form the foundation of this review.

REFERENCES

[1] Morya AK, Kumari R, Nayak S, et al. Diabetic retinopathy: A review on its pathophysiology and treatment approaches. *Indian J Ophthalmol*. 2024;72(3):389–401.

[2] Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045. *Ophthalmology*. 2021;128(11):1580–1591.

[3] Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35(3):556–564.

[4] Wang W, Lo ACY. Diabetic retinopathy: Pathophysiology and treatments. *Int J Mol Sci*. 2018;19(6):1816.

[5] Yang Z, Tan TE, Shao Y, et al. Classification of diabetic retinopathy: Past, present and future. *Front Endocrinol (Lausanne)*. 2022;13:1079217.

[6] Chhablani J, Sharma A, Goud A, et al. Recent advances in the treatment and delivery system of diabetic retinopathy. *Front Endocrinol (Lausanne)*. 2024;15:1347864.

[7] Ciulla TA, Pollack JS, Williams DF. Visual outcomes in patients with diabetic macular edema: A systematic review. *Expert Opin Pharmacother*. 2022;23(11):1275–1295.

[8] Wei L, Sun X, Fan C, et al. The pathophysiological mechanisms underlying diabetic retinopathy. *Front Cell Dev Biol*. 2022;10:963615.

[9] Lee SHS, Yoo JH, Ghim MW, et al. mTOR inhibition as a novel gene therapeutic strategy for diabetic retinopathy. *PLoS One*. 2022;17(6):e0269951.

[10] Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet*. 2010;376(9735):124–136.

[11] Lechner J, O'Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. *Vision Res*. 2017;139:7–14.

[12] Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. *Exp Diabetes Res*. 2007;2007:43603.

[13] Frontiers in Endocrinology Task Force. Recent advances in the treatment and delivery system of diabetic retinopathy. *Front Endocrinol (Lausanne)*. 2024;15:1347864.

[14] Cheung N, Mitchell P, Wong TY. The role of systemic risk factors in diabetic retinopathy. *Transl Vis Sci Technol*. 2016;5(2):8.

[15] Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. *Arch Ophthalmol*. 1985;103(12):1796–1806.

[16] Urbančič M, Petrovski G, Kobal A, et al. Dexamethasone implant in the management of diabetic macular edema. *Clin Ophthalmol*. 2019;13:879–886.

[17] Chen YY, Wang MT, Wu YC, et al. Real-world treatment patterns and visual outcomes of faricimab in diabetic macular oedema. *Eye (Lond)*. 2025;39(2):345–352.

[18] Kupis M, Górski M, Penkala K, et al. Novel therapies for diabetic retinopathy. *Arch Med Sci*. 2022;18(1):207–214.

[19] Zhang W, Wang Y, Kong Y, et al. Therapeutic efficacy of neural stem cells originating from umbilical cord-derived mesenchymal stem cells in diabetic retinopathy. *Sci Rep*. 2017;7:408.

[20] Hwu CM, Chen JF, Tsai IT, et al. Comparison of sight-threatening diabetic retinopathy in patients with type 2 diabetes receiving SGLT2 inhibitors versus other glucose-lowering agents. *JAMA Netw Open*. 2024;7(1):e2350676.

[21] Vashist P, Singh S, Gupta N, et al. Role of early screening for diabetic retinopathy in patients with diabetes mellitus. *Indian J Community Med*. 2011;36(4):247–252.

[22] Raman R, Ramasamy K, Rajalakshmi R, et al. Diabetic retinopathy screening guidelines in India. *Indian J Ophthalmol*. 2020;68(Suppl 1):S3–S12.